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Oral estrogen administration attenuates the metabolic action of
growth hormone (GH) in humans. To investigate the mechanism
involved, we studied the effects of estrogen on GH signaling through
Janus kinase (JAK)2 and the signal transducers and activators of
transcription (STATs) in HEK293 cells stably expressing the GH recep-
tor (293GHR), HuH7 (hepatoma) and T-47D (breast cancer) cells.
293GHR cells were transiently transfected with an estrogen recep-
tor- expression plasmid and luciferase reporters with binding ele-
ments for STAT3 and STAT5 or the -casein promoter. GH stimulated
the reporter activities by four- to sixfold. Cotreatment with 17-
estradiol (E2) resulted in a dose-dependent reduction in the response
of all three reporters to GH to a maximum of 49–66% of control at 100
nM (P < 0.05). No reduction was seen when E2 was added 1–2 h after
GH treatment. Similar inhibitory effects were observed in HuH7 and
T-47D cells. E2 suppressed GH-induced JAK2 phosphorylation, an
effect attenuated by actinomycin D, suggesting a requirement for
gene expression. Next, we investigated the role of the suppressors of
cytokine signaling (SOCS) in E2 inhibition. E2 increased the mRNA
abundance of SOCS-2 but not SOCS-1 and SOCS-3 in HEK293 cells. The
inhibitory effect of E2 was absent in cells lacking SOCS-2 but not in
those lacking SOCS-1 and SOCS-3. In conclusion, estrogen inhibits GH
signaling, an action mediated by SOCS-2. This paper provides evi-
dence for regulatory interaction between a sex steroid and the
GHJAKSTAT pathway, in which SOCS-2 plays a central mechanistic
role.
Growth hormone (GH) plays a major role in regulating somaticgrowth and substrate metabolism (1). It exerts the action via
specific GH receptors (GHRs) in target tissues (2). GHR is a
transmembrane protein, which, together with the receptors for
prolactin and IL6, are members of the cytokine receptor family (3).
Upon ligand binding, GHRs dimerize and induce activation and
phosphorylation of Janus kinase (JAK)2 (4), which then phosphor-
ylates GHRs and the signal transducers and activators of transcrip-
tion (STATs), including STAT1, -3, and -5 (5). The STAT proteins
dimerize and translocate to the nucleus, where they bind to specific
DNA motifs within the promoter regions of GH-responsive genes
to initiate transcription (6).
GH activation of the JAKSTAT pathway is negatively reg-
ulated by phosphotyrosine phosphatases and the suppressors of
cytokine signaling (SOCS). Phosphatases, such as SHP1 and -2,
inactivate JAK2 in a GH-dependent manner (7, 8). SOCS
consists of a family of inhibitors, which suppress JAKSTAT
signaling by a wide variety of cytokines, hormones, and growth
factors (9). GH induces the expression of SOCS-1, -2, and -3,
which feed back to inhibit its transcriptional action (10, 11).
There is strong evidence that estrogen negatively regulates
GH action. Oral estrogen administration to women reduces
serum levels of insulin-like growth factor I, despite elevating GH
levels (12, 13), and suppresses GH stimulation of lipid oxidation
(14). Moreover, women are less responsive than men to GH
treatment (15). The mechanism of estrogen inhibition of GH
action is unknown.
Estrogen action is mediated by specific nuclear estrogen
receptors (ERs), which are ligand-activated transcription factors
belonging to the steroid hormone receptor family (16). There is
evidence of crosstalk between signaling pathways of steroid
hormone and cytokine receptors. Ligand-bound glucocorticoid
receptor (GR) directly associates with STAT5 and enhances
prolactin-activated JAKSTAT signaling (17, 18).
In this study, we investigated the effects of estrogen on the
transcriptional action of GH through the JAKSTAT pathway,
and examined the roles of phosphotyrosine phosphatases and
SOCS in estrogen regulation of GH action.
Materials and Methods
Reagents and Plasmids. Recombinant human GH was produced
in-house (19). Human prolactin and IL6 were obtained from
National Institute of Diabetes and Digestive and Kidney Diseases
(Bethesda) and R & D Systems, respectively. ICI182780 was
obtained from ICI. All cell culture reagents, calcium phosphate
precipitation transfection kit, and TRIzol reagent were obtained
from GIBCOBRL. Omniscript reverse transcription kit and non-
liposomal (Effectene) transfection reagent were obtained from
Qiagen (Clifton Hill, Victoria, Australia). Lysis reagent and lucif-
erase assay system were purchased from Promega (Madison, WI);
Galacto Light was obtained from Tropix (Bedford, MA). Rabbit
polyclonal antibodies against JAK2 (HR-758), STAT3 (KR-15),
STAT5 (C-17), ER (H-184), and GR (P-20) were obtained from
Santa Cruz Biotechnology. The anti-phosphotyrosine monoclonal
antibody (4G10) was obtained from Upstate Biotechnology (Lake
Placid, NY). ImmunoPure Protein AG agarose gel was obtained
from Pierce. Complete protease inhibitor mixture (with inhibitors
for serine, cysteine, metalloproteases, and calpains) and Light-
Cycler-Fast Start Reaction Mix SYBR Green I were obtained from
Roche Molecular Biochemicals. PolyScreen poly(vinylidene) diflu-
oride membrane and Renaissance chemiluminescence reagent
were obtained from NEN.
The human GHR expression plasmid (pcDNAIAmp-
GHRfl) was generated as reported (20). Expression plasmids
for human ER (pCMV-ERgly-neo), human STAT3, murine
STAT5a (pCDNA3-mSTAT5a), and -galactosidase (-Gal;
IEP-gal-CMV) were provided by Craig Jordan (Robert H.
Lurie Cancer Center, Chicago), James Darnell (The Rockefeller
University, New York), Bernard Callus (Garvan Institute of
Medical Research, Sydney) and Gerald Clesham (University of
Cambridge, Cambridge, U.K.), respectively. Luciferase reporter
constructs with three copies of m67, a high-affinity mutated
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form of c-sis-inducible element for STAT3 binding (5-
CTGCAGTCGACATTTCCCGTAAATCGTCGACTGCA-3;
pUC18-SIE m67TK), or with six copies of a synthetic lactogenic
hormone response element for STAT5 binding (5-CTGCAGT-
GTGGACTTCTTGGAATTAAGGGACTTTTGCTGCAG-
3; pUC18-LHRETK) fused to a minimal thymidine kinase
promoter (21) were provided by Paul Kelly (Faculte de Me-
decine Necker, Paris). Luciferase reporter constructs containing
an NdeI-XhoI fragment of the rat -casein promoter (nucleo-
tides 344 to 1) in a pLucDSS plasmid (pZZ1; ref. 22) or a
consensus estrogen response element (ERE; 5-AGGTCACT-
GTGACCT-3) in a minimal TK GL3 plasmid (pERETKGL3;
ref. 23) were provided by Bernd Groner (Institute of Experi-
mental Cancer Research, Freiburg, Germany) and Malcolm
Parker (Imperial Cancer Research Fund, London), respectively.
PCR primers for human SOCS-1 (forward, 5-AGACCCCT-
TCTCACCTCTTG-3; reverse, 5-CTGCACAGCAGAAAAA-
TAAAGC-3; ref. 24), SOCS-2 (forward, 5-GGATGGTACTG-
GGGAAGTATGACTG-3; reverse, 5-AGTCGATCAGAT-
GAACCACACTGTC-3); and SOCS-3 (forward, 5-TCCCC-
CCAGAAGAGCCTATTAC-3; reverse, 5-TCCGACAGAG-
ATGCTGAAGAGTG-3) were obtained from Sigma Genosys
(Sydney). Double-stranded short interfering RNA (siRNA)
fragment (5-AAGACCCAGTCTGGGACCAAGAA-3) for
nucleotides 359–381 of the human SOCS-3 gene for RNA
interference assay was obtained from Xeragon (Huntsville, AL).
Cell Cultures. HEK293 cells stably expressing human GHR
(293GHR; ref. 25) were routinely grown at 37°C in 5% CO295%
air in DMEMF-12 supplemented with 10% (vol/vol) FCS25 mM
Hepes2 mM L-Gln50 units per ml of penicillin50 g/ml strep-
tomycin. HuH7, T-47D, and primary embryonic fibroblasts from
SOCS-1- or SOCS-2-deficient (SOCS-1/ and SOCS-2/, respec-
tively) and wild-type (C57BL6) mice (provided by Warren Alex-
ander and Christopher Greenhalgh, Walter and Eliza Hall Institute
of Medical Research, Melbourne; ref. 26) were cultured in Eagle’s
minimal essential medium, RPMI medium 1640, and DMEM,
respectively. All cultures were changed to phenol red-free medium
supplemented with 10% charcoal-stripped FCS for 3 days before
use. All experiments were performed in phenol red-free medium
under serum-free conditions.
Transcription Assays. 293GHR cells in 12-well multidishes were
transiently transfected for 24 h with expression plasmids for ER
(0.1 g) and -Gal (0.01 g), luciferase reporters with the STAT3-
or STAT5-binding elements or with a rat -casein promoter (0.1
g) by using the calcium phosphate precipitation method. Expres-
sion plasmids for STAT3 (0.2 g) and STAT5a (0.05 g) were
cotransfected in the STAT3 and -casein reporter assays, respec-
tively. The cells were then treated in triplicate with 500 ngml GH
and varying concentrations of 17-estradiol (E2) at 37°C for 6 or
18 h. Because dexamethasone (Dex) has been shown to enhance the
STAT5 response to GH (27), 250 nM Dex was added in the STAT5
reporter assay. The cells were solubilized in lysis reagent [25 mM
Tris, pH 7.8, with 2 mM trans-1,2-diaminocyclohexane-N,N,N,N-
tetraacetic acid, 2 mM DTT, 10% (volvol) glycerol, and 1% Triton
X-100]. Luciferase and -Gal activities were measured by the
luciferase assay system and Galacto Light, respectively. Luciferase
activity was normalized for -Gal activity and reported as fold
induction compared with the untreated control.
The effects of E2 on STAT5 reporter activation by GH were also
examined in human hepatoma (HuH7) and breast cancer cells
(T-47D), and in fibroblasts from wild-type, SOCS-1/, and SOCS-
2/ mice. Coexpression with GHR and ER was performed in
HuH7 cells and fibroblasts but not in T-47D cells, which express
both receptors endogenously (28, 29). Transfection was carried out
by using the Effectene reagent. The subsequent procedures of
treatment and enzyme assays were the same as for 293GHR cells.
Western Analysis. The effects of E2 on GH-induced phosphorylation
of JAK2, STAT3, and STAT5 in 293GHR cells and on JAK2
phosphorylation in HuH7 cells and fibroblasts were examined by
Western analysis. Cells expressing ER (and GHR in HuH7 and
fibroblasts) were pretreated with 100 nM E2 at 37°C for 2.5 h and
then with 500 ngml GH for 2 min (JAK2) or 1 h (STAT3 and
STAT5). The cells were washed with 1 mM sodium orthovanadate
(vanadate) in PBS and solubilized in lysis buffer (50 mM Tris, pH
7.20.14 M NaCl10 mM NaF1 mM vanadate0.4% Triton
X-100) with Complete protease inhibitor mixture. Lysates were
incubated with 2g of antibodies against JAK2, STAT3, or STAT5
at 4°C for 18 h and precipitated with ImmunoPure Protein AG
agarose gel. The samples were resolved by SDSPAGE on 7.5% gel
and blotted onto poly(vinylidene) difluoride membrane. The mem-
brane was treated sequentially with blocking buffer (20 mM
TrisHCl, pH 7.4150 mM NaCl1% BSA0.1% Tween-20), anti-
phosphotyrosine antibody (4G10, 5 g5 ml), and sheep anti-
mouse Ig-horseradish peroxidase. The bands were visualized by
chemiluminescence and quantified by densitometry.
Protein abundance of JAK2, STAT3, and STAT5 was deter-
mined after stripping the membrane with 62.5 mM TrisCl, pH 6.8,
100 mM 2-mercaptoethanol, and 2% SDS at 50°C for 30 min. The
membrane was treated with blocking buffer containing 5% skim
milk powder in place of BSA and probed with 5 g5 ml of
antibodies against JAK2, STAT3, or STAT5. The signal was
developed with donkey anti-rabbit Ig-horseradish peroxidase by
chemiluminescence and quantified by densitometry. Levels of
phosphorylated JAK2 and STAT were corrected for protein abun-
dance, and reported as percentages of control treated with GH
alone.
SOCS mRNA. The mRNA abundance of SOCS-1, -2, and -3 in
HEK293 cells treated with E2 or GH was quantified by reverse
transcription accompanied by real-time PCR. HEK293 cells ex-
pressing ER and GHR were treated in triplicate with 100 nM E2
or 500 ngml GH for 0.25, 0.5, 1, 2, and 4 h. At the indicated time,
total RNA was extracted by using TRIzol reagent. Reverse tran-
scription was performed by using the Omniscript reverse transcrip-
tion kit as recommended by the manufacturer, in which 0.5 g of
RNA and oligo-dT primer were used. Controls with no reverse
transcriptase were included.
Standards for real-time PCR were constructed for the SOCS by
PCR using respective primer sets and plasmids containing the
human SOCS genes as templates (30, 31). Real-time PCR assays
were carried out in a LightCycler (Roche Molecular Biochemicals)
with a 20-l final volume containing 2 l of sample cDNA or
standards, 5 mM MgCl2, 0.5 M primers, and 2 l of LightCycler-
Fast Start Reaction Mix SYBR Green I. The amplification program
included an initial denaturation step at 95°C for 10 min, followed
by 40 cycles of denaturation at 95°C for 0.5 s, annealing at 55°C for
5 s and extension at 72°C for 10 s, with ramping rates at 20°Cs. The
specificity of amplification was subjected to melting curve analysis
by heating from 65°C to 95°C at the rate of 0.1°Cs. Amplification
curves were plotted as fluorescence signal against cycle number,
and the first turning point (crossing point) was obtained for each
sample by using the Second Derivative Maximum Method (Roche
Molecular Biochemicals). Values of crossing point for standards
were used to construct a calibration curve, from which copy
numbers for the samples were estimated. All samples were assayed
at the same time for statistical comparison.
SOCS-3 RNA Interference. To examine whether SOCS-3 was involved
in the E2 regulation, its expression was selectively suppressed by
using the RNA interference method (32). HEK293 cells were
transiently transfected with SOCS-3 siRNA (8 nM), expression
plasmids for ER, GHR, and -Gal, and the STAT5 reporter by
using the Effectene reagent. Cells cotransfected with an expression
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plasmid for human SOCS-3 (50 ng) were included to assess the
efficiency of RNA interference.
Statistical Analysis. All experiments were repeated three times
unless stated otherwise. Mean  SE of results from multiple
experiments of the same study are reported. Data were analyzed by
Student’s paired t test or ANOVA (STATVIEW V.4.5, Abacus Con-
cepts, Berkeley, CA) where appropriate, and significance was set at
P  0.05.
Results
STAT5, STAT3, and -Casein Reporters in 293GHR. GH stimulated
STAT5 reporter response by 6.8  0.8 fold (n  4; P  0.01; Fig.
1a). E2 reduced the response in a dose-dependent manner, with
significant inhibition at 0.1 nM (76 6% of control; P 0.05) and
maximal reduction at 1,000 nM (59 1%; P 0.01). The inhibitory
effect was not detected without ER expression (data not shown)
and was attenuated by pretreatment with 1 M ICI182780, an
anti-estrogen (n  4; P  0.05; Fig. 1b).
To study the time course of E2 inhibition, 293GHR cells were
treated with 100 nM E2 before, during, and after a 1-h pulse of GH.
Pretreatment with E2 for 1 and 2 h reduced the reporter response
to 62 6% and 63 3% of control, respectively (n 4; P 0.01;
Fig. 1c). E2 added together with GH had a lesser effect (71  6%;
P 0.05), whereas no inhibition was detected with E2 addition after
the GH pulse.
Fig. 1d shows the effect of E2 on GH transcriptional action
mediated by STAT3. As with STAT5, E2 reduced the STAT3
reporter response to GH in a dose-dependent manner from 4.3 
0.4-fold to 2.8  0.2-fold at 100 nM (n  4; P  0.05).
To determine whether E2 inhibition occurred on a natural
promoter, we examined the effect on GH activation of a -casein
promoter reporter in 293GHR cells expressing exogenous STAT5a.
GH induced the reporter activity by 3.8  0.5-fold (P  0.01; Fig.
1e). Cotreatment with E2 reduced the response to 49  4% of
control at 100 nM (P  0.05). Similar results were observed in
T-47D cells expressing exogenous STAT5a (data not shown).
STAT5 Reporter in HuH7 and T-47D. To examine whether E2 inhibited
GH transcriptional action in other cell types, studies were per-
formed in HuH7 (hepatoma) and T-47D (breast cancer) cells. In
HuH7 cells coexpressing GHR and ER, GH activated the STAT5
reporter by 2.3  0.2-fold (n  8; P  0.01). The response was
inhibited by E2, with a maximal reduction to 76 7% of control at
1,000 nM (P  0.01; data not shown). Similarly, E2 at 100 nM
reduced the GH-induced response in T-47D cells from 9.3 
1.5-fold to 7.0  1.2-fold (n  4; P  0.01; data not shown).
Prolactin and IL6 Signaling. Next, we studied the effects of E2 on
JAKSTAT signaling of other cytokines, namely prolactin and IL6.
In T-47D cells which express endogenous prolactin receptors (33),
prolactin stimulated STAT5 reporter activity by 2.8 0.4-fold (n
4; P 0.05). The response was reduced by E2 to 74 4% of control
(P  0.05; Fig. 2a).
The effect on IL6 signaling was studied in HEK293 cells with
endogenous IL6 receptor and exogenous STAT3 (27). IL6 activated
the STAT3 reporter by 1.8  0.1-fold (P  0.01), and 100 nM E2
reduced the response to 75  2% of control (P  0.05; Fig. 2b).
Fig. 1. Effects of E2 on GH transcriptional activity in 293GHR cells. (a) Cells were
transiently transfected with an ER expression plasmid and STAT5 reporter and
treated with 500 ngml GH and 250 nM Dex and E2 at indicated concentrations
for 6 h. *, P 0.05; †, P 0.01. (b) Effect of anti-estrogen. After pretreatment for
30 min with 1M ICI182780, the cells were incubated with 500 ngml GH and 250
nM Dex and E2 for 6 h; vs. control with E2 at corresponding concentrations, *, P
0.05. (c) Time course of E2 effect. The cells were treated with a 1-h pulse of 500
ngml GH, washed, and incubated in fresh medium for a further 5 h before
luciferaseactivitymeasurement.E2 at100nMwasaddedat indicatedtimebefore
(minus) or after (plus) the GH pulse. For2,1, and 0 h, E2 was replaced in fresh
medium during the 5-h incubation without GH. Control cultures without E2 were
set up for each time point. Luciferase activity of E2-treated samples is presented
aspercentageofnon-E2-treatedcontrolof thesametimepoint; vs. controlsat the
same time point: *, P  0.01; †, P  0.05. (d) STAT3 reporter. Cells expressing
exogenous STAT3 and ERwere transiently transfected with the STAT3 reporter
and treated with 500 ngml GH and E2 at indicated concentrations for 6 h. *, P
0.05. (e)-Casein promoter reporter. Cells expressing exogenous STAT5a and ER
were transiently transfected with the -casein promoter reporter and treated
with 500 ngml GH and 250 nM Dex and E2 for 24 h. *, P 0.05.
Fig. 2. Effects of E2 on transcriptional activities of prolactin and IL6. (a) T-47D
cells transfected with the STAT5 reporter were treated for 24 h with 500 ngml
prolactin and 250 nM Dex and E2. *, P 0.05. (b) 293GHR cells transfected with
the STAT3 reporter and expression plasmids for ER and STAT3 were treated for
24 h with 500 ngml IL6 and E2. *, P 0.05.
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ERE Reporter. Having demonstrated the inhibitory effect of E2 on
GH signaling, we examined whether GH exerted a reciprocal effect
on E2 action by using an ERE reporter. E2 increased the reporter
activity in a dose-dependent manner to a maximum of 1.6 0.1-fold
and 10.9  2.8-fold at 100 nM in 293GHR and T-47D cells,
respectively (n  4; P  0.01). GH at 500 ngml did not affect the
stimulation at any concentration of E2 (data not shown).
Dex-Enhanced STAT5 Reporter Activity. As Dex was used in the
STAT5 reporter assay to enhance response (17), we examined
whether the effect of E2 depended on the presence of glucocorti-
coid. GH-induced STAT5 activity was significantly lower in the
absence than the presence of 250 nM Dex (9.1 0.6-fold and 19.6
1.0-fold, respectively; P 0.01). However, the reporter response to
GH was inhibited to a similar extent by 1,000 nM E2 without or with
Dex (55 2% and 58 1% of control, respectively; P 0.01; data
not shown).
STAT Phosphorylation. To elucidate the mechanism of E2 inhibition,
its effects on GH-induced phosphorylation of STAT3 and STAT5
were studied by Western blotting (Fig. 3). GH stimulation of STAT
phosphorylation was reduced by E2 to 62 7% (P 0.05) and 50
4% of GH-treated control (P 0.01), respectively. Neither GH nor
E2 affected protein abundance of the STATs.
Interaction of STAT5 with ER and GR. As GR directly associates with
STAT5 to modulate its transcriptional activity (17), we investigated
whether ER bound to STAT5 by coimmunoprecipitation. As
shown in Fig. 4a, STAT5 was coprecipitated with an anti-GR
antibody, revealing association of STAT5 with GR. Similarly, GR
was coprecipitated with an anti-STAT5 antibody, and the associa-
tion was enhanced by GH treatment (Fig. 4b). In contrast, the
STAT5 band was not detected in the precipitates of an antibody to
ER (Fig. 4a), nor was ER coprecipitated with an anti-STAT5
antibody (Fig. 4c).
JAK2 Phosphorylation. Having demonstrated that E2 exerted similar
effects on the activation of STAT3 and STAT5, we examined
whether the inhibition resulted from suppression of JAK2 phos-
phorylation. GH markedly induced JAK2 phosphorylation in
293GHR (Fig. 5a) and HuH7 cells (Fig. 5b), and E2 reduced this
response to 50  3% and 48  3% of control, respectively (n  6;
P  0.01). In contrast to E2, Dex did not affect JAK2 phosphor-
ylation in 293GHR cells (Fig. 5c).
Actinomycin D. As ER is a transcription factor, we studied whether
de novo gene expression was required for the E2 inhibition. As
shown previously, E2 decreased GH-induced JAK2 phosphoryla-
tion to 52  7% of control in the absence of actinomycin D (Fig.
6a). Pretreatment for 1 h with 5 gml actinomycin D completely
abolished this effect (95  5% of control), suggesting that E2
inhibition of GH signaling is indirectly mediated and requires the
expression of another factor(s).
Vanadate. We examined the role of phosphotyrosine phosphatases
in E2 inhibition by using vanadate, a general inhibitor of phospha-
tases (34, 35). Pretreatment for 1 h with 1 mM vanadate did not
affect E2 inhibition of GH-induced JAK2 phosphorylation (48 
4% vs. 43  6%, without and with vanadate, respectively; Fig. 6b).
In the STAT5 reporter assay, vanadate did not affect the inhibitory
effect of E2 at concentrations up to 100 nM (data not shown). Thus,
phosphotyrosine phosphatases do not appear to be involved in the
E2 inhibition.
SOCS. Next, we investigated the role of SOCS proteins by studying
the effects of E2 on expression of SOCS-1, -2, and -3. In HEK293
cells expressing GHR and ER, SOCS-2 mRNA abundance in-
Fig. 3. Western blotting of tyrosine phosphorylation (PY) of STAT3 (a) and
STAT5(b) in293GHRcells.Thecellsweretreatedfor2.5hwith100nME2 andthen
for 1 h with 500 ngml GH (also with 250 nM Dex in the case of STAT5), as
indicated. Cell lysates were immunoprecipitated with antibodies for STAT3 or
STAT5 and Western blotted with an anti-phosphotyrosine antibody (Upper) and
the anti-STAT antibodies (Lower).
Fig. 4. Coimmunoprecipitation of STAT5 with GR and ER in 293GHR cells.
Western blots of STAT5 (a), GR (b), and ER (c) in 293GHR cells treated for 1 h with
250 nM Dex, without or with 500 ngml GH and 100 nM E2, and precipitated (IP)
with antibodies against STAT5, GR, or ER, as indicated. The bottom bands (Ig)
were the heavy chains of the antibodies used for immunoprecipitation.
Fig. 5. Regulation of GH-induced phosphorylation of JAK2 by E2 in 293GHR (a)
and HuH7 (b) cells, or by Dex in 293GHR cells (c). The cells were treated for 2.5 h
with 100 nM E2 or 250 nM Dex and then for 2 min with 500 ngml GH as indicated,
followed by immunoprecipitation for JAK2 and Western blotting for phosphor-
ylated (PY) and total JAK2. Arrowheads indicate nonspecific bands.
Fig. 6. Effects of actinomycin D and vanadate in 293GHR cells. Western blots of
GH-induced tyrosine phosphorylation (PY) of JAK2 in 293GHR cells treated for 1 h
with 5 gml actinomycin D (a; Act D) or 1 mM vanadate (b), followed by
treatment for 2.5 h with 100 nM E2 and for 2 min with 500 ngml GH, as indicated.
Arrowheads indicate nonspecific bands.
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creased significantly to 1.7  0.1-fold of control at 1 h of GH
treatment (P 0.01; Fig. 7a) and rose progressively to 3.7 0.3-fold
at 4 h (P  0.01). E2 also induced a time-dependent increase in
SOCS-2 mRNA abundance by 1.7 0.1-fold at 1 h (P 0.01), and
no further increase was observed thereafter. The mRNA abun-
dance of SOCS-1 and -3 was unaffected by GH or E2 treatment
(data not shown).
Then, we examined the effects of E2 on GH activation of the
STAT5 reporter and JAK2 phosphorylation in wild-type, SOCS-
1/, and SOCS-2/ fibroblasts. GH activated the reporter activity
by three- to sixfold in these cells. In wild-type and SOCS-1/
fibroblasts, the response was reduced by E2 to 63  3% and 63 
4% of control, respectively (P  0.01; Fig. 7b), but unchanged in
SOCS-2/ cells. E2 also suppressed GH-induced JAK2 phosphor-
ylation in wild-type and SOCS-1/ fibroblasts to 47 3% and 50
4% of control, respectively (P 0.01; Fig. 7c), but not in SOCS-2/
cells (98  5%).
The role of SOCS-3 in E2 inhibition was studied by using the
RNA interference method, as cells lacking the SOCS-3 gene are
unavailable. Efficiency of this method was examined by transiently
transfecting HEK293 cells with the SOCS-3 siRNA and expression
plasmids for ER, GHR, and SOCS-3. SOCS-3 expression fully
blocked GH activation of the STAT5 reporter (2.0  0.1-fold vs.
1.1  0.1-fold; P  0.01; Fig. 7d). The siRNA cotransfection
increased the response to 90 1% of control (P 0.01). The RNA
interference effect was specific for SOCS-3, as no effect on SOCS-1
and SOCS-2 on GH signaling was observed (data not shown).
The effect of SOCS-3 siRNA on E2 inhibition of GH action was
examined next. E2 reduced the reporter response to a similar extent
in cells with or without siRNA transfection (69 6% and 64 1%
of control, respectively; P 0.05; Fig. 7e). Thus, the collective data
suggest that SOCS-2, rather than SOCS-1 and -3, is involved in the
E2 inhibition.
Discussion
This study was instigated by clinical observations in our labora-
tory that oral estrogen administration antagonizes the metabolic
action of GH (14, 36). We demonstrated that estrogen inhibited
the transcriptional action of GH via the JAKSTAT pathway.
The effect was ER-mediated and involved suppression of both
STAT3 and STAT5 signaling. Similar inhibitory effects were
detected for prolactin and IL6. The inhibition of GH action was
effective only with prior exposure to estrogen. A direct interac-
tion of ER with STAT5 was not evident. Estrogen suppressed
GH-induced phosphorylation of JAK2 and STATs, an effect not
affected by phosphotyrosine phosphatase inhibition but abol-
ished by actinomycin D, indicating a dependency on gene
transcription. Estrogen increased the mRNA abundance of
SOCS-2 but not of SOCS-1 or -3. The inhibition of GH signaling
was absent in cells lacking SOCS-2 but not the other SOCS. This
evidence demonstrates that a steroid hormone regulates SOCS
expression, which in turn modulates GH signaling.
There are multiple sites for estrogen inhibition of GH action.
Estrogen may reduce GHR availability by down-regulating receptor
expression, or it may suppress GH signaling. Most previous studies
focus on GHR expression as the mechanism and show that estrogen
increases GHR mRNA level in rodents (37). The effect on human
GHR is not clear. In our study, no effect of estrogen on GH binding
was observed in 293GHR cells (unpublished observations). This
observation is predictable because GHR expression in these cells is
controlled by an exogenous viral promoter, which is not estrogen-
responsive. These findings also led us to investigate the effects of
estrogen on GH signaling via the JAKSTAT pathway.
We first examined possible association of ER with STAT5
based on evidence of crosstalk between glucocorticoid and prolac-
tin signaling occurring through direct interaction of GR with
STAT5 (38). Stoecklin et al. (17) have shown that glucocorticoid
enhances JAKSTAT activation by prolactin, and that the mech-
anism involves GR associating with and acting as a coactivator of
STAT5. We extended these findings by showing that glucocorticoid
enhancement of GH-induced STAT5 activation was associated with
GR interaction with endogenous STAT5. On the other hand, we
found no evidence for ER interaction with STAT5, which suggests
that estrogen inhibition of GH signaling is unlikely to arise from
sequestering of STAT5 by ER. As STAT5 binds to GR at the
activation function 1 domain (39), a region known to be highly
heterogeneous among steroid hormone receptors, the present
findings suggest that ER does not contain such an interactive site
for STAT5. However, our findings are in conflict with the recent
reports that ERs associate with exogenously expressed STAT3 (40)
and STAT5 (41). The reason for the discrepancy is unclear but
could relate to differences in experimental conditions, as the
association of ERs with STAT3 and STAT5 was detected under
conditions of STAT over-expression. It is unlikely that technical
factors accounted for our inability to demonstrate this interaction
because association between endogenous STAT5 and GR was
observed under similar experimental conditions.
The observation that estrogen inhibited GH activation of
STAT3 and STAT5 led us to examine whether this effect was
exerted upstream at the level of JAK2 activation. The suppres-
sion of GH-induced JAK2 phosphorylation by estrogen stands in
contrast to the effect of glucocorticoid, which is exerted at the
level of STAT5 activation, an observation also reported by von
Fig. 7. SOCS. (a) Effects of E2 and GH on SOCS-2 expression in HEK293 cells
expressing ER and GHR. The cells were treated with 100 nM E2 or 500 ngml GH
for time as indicated. SOCS-2 mRNA abundance was quantified by reverse tran-
scription and real-time PCR; vs. respective control at time 0: *, P0.01; †, P0.05.
(b) Effects of E2 (1 nM) on STAT5 activation by GH (500 ngml) in wild-type (WT)
and SOCS-deficient fibroblasts expressing ER and GHR. Results are expressed as
percentages of GH-treated control for the respective cell lines. *, P  0.01.
(c) Western blots of GH-induced JAK2 phosphorylation (PY) in the fibroblasts
treated for 2.5 h with 1 nM E2 and then for 2 min with 500 ngml GH, as indicated.
Arrowheads indicate nonspecific bands. (d) Effects of SOCS-3 siRNA transfection
on GH activation of STAT5 reporter in HEK293 cells expressing SOCS-3. The cells
were transiently transfected with a GHR expression plasmid, a STAT5 reporter,
with or without SOCS-3 siRNA (8 nM) and a SOCS-3 expression plasmid (50 ng), as
indicated, and then treated for 3 h with 500 ngml GH and 250 nM Dex. Data
shown are the mean SE of triplicate measurements in a representative exper-
iment, which was repeated twice; vs. respective control without SOCS-3: *, P 
0.01, †, P0.05; vs. sample without siRNA and with SOCS-3: ‡, P0.01. (e) Effects
of SOCS-3 siRNA on E2 inhibition of GH-induced STAT5 activity in HEK293 cells.
Cells expressing ER and GHR were cotransfected with or without SOCS-3 siRNA
(8 nM) and treated for 3 h with 500 ngml GH and 250 nM Dex and E2 at indicated
concentrations. Data shown are the mean SE of triplicate measurements in a
representative experiment, which was repeated twice; vs. respective control: *,
P 0.01; †, P 0.05.
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Laue et al. (27). The collective data reveal that estrogen and
glucocorticoid exert opposite effects on GH signaling through
different mechanisms.
Estrogen inhibition of GH signaling was uniformly observed in
all cell types tested, except SOCS-2/ fibroblasts. Because most of
these studies were performed after transfection with ER and
GHR, it is possible that the inhibition might be a squelching effect
of estrogen resulting from competition of limited factors for gene
transcription. However, this possibility is unlikely because similar
inhibitory effects were detected in T-47D cells, which express
endogenous ERs and GHRs. These data suggest that the inhibition
of GH signaling is a specific effect of estrogen.
The study with actinomycin D revealed that the inhibition of GH
signaling was not a direct effect of ER. This finding is consistent
with the view that estrogen functions mainly through effects on gene
transcription (42). Results of the time course study also suggest
indirect inhibition by a factor expressed in response to estrogen.
Pretreatment with estrogen was required for effective inhibition of
GH signaling, probably reflecting the time for synthesis of the
factor.
Phosphotyrosine phosphatases and SOCS were considered likely
candidates for mediating the inhibitory action of estrogen. The
studies with vanadate, however, did not support a role for phos-
photyrosine phosphatases. We then investigated whether SOCS
proteins mediated the estrogen inhibition. Estrogen stimulated the
expression of SOCS-2 in HEK293 cells. The stimulation was acute
and significant by 1 h, and remained elevated by 4 h. GH also
stimulated SOCS-2 expression, confirming and extending similar
observations in rodents (10, 43). Unlike SOCS-2, we found no
evidence for regulation of SOCS-1 and SOCS-3 expression by
estrogen and GH in HEK293 cells. This observation of GH
contrasts with previous reports that GH acutely and transiently
stimulates expression of these two SOCS proteins in rat hepatocytes
(10, 43). It is unclear whether the differences arise from tissue or
species-specific effect.
The studies with SOCS-deficient cells and RNA interference
revealed SOCS-2 and not SOCS-1 or -3 to be the key mediator of
estrogen inhibition of GH signaling. There is strong evidence from
gene knockout studies that SOCS-2 is an important negative
regulator of GH action. SOCS-2/ mice display a phenotype of
excess growth (44) similar to that of GH-transgenic mice (45). The
absence of a giant phenotype in the SOCS-2STAT5b double-
knockout mice (26) suggests the importance of SOCS-2 regulation
of GH action mediated by the JAKSTAT pathway and hence the
potential significance of estrogen inhibition.
The induction of GH resistance by estrogen may explain, in part,
the gender differences in GH levels and responsiveness to GH
treatment (15). Estrogen inhibition of the JAKSTAT signaling by
prolactin and IL6 may have wider physiologic implications because
of the pivotal role of this signaling pathway in mediating signal
transduction of cytokine receptors (46). We speculate that the
inhibition by estrogen of prolactin-induced lactation, the sexual
dimorphism in red cell mass, and the modulatory role of estrogen
in immune function may be underpinned by a broader role in
regulating cytokine signaling involving SOCS protein.
In conclusion, estrogen inhibits GH signaling via the JAKSTAT
pathway by suppressing JAK2 phosphorylation, an effect exerted
through stimulation of SOCS-2. This is a mechanism of sex steroid
regulation of GH action, and may have significance beyond estro-
gen and GH action.
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